Natera (NTRA) is back in focus after a busy early November, with Q3 2026 results, higher full year revenue guidance, fresh Signatera cancer data and a CEO transition all landing together.
Recent trading shows that momentum in Natera’s share price has cooled in the short term, with a 7 day share price return of down 15.45% and a 30 day move of down 20.04%. At the same time, the 90 day share price return sits at 2.45% and the 1 year total shareholder return reaches 55.05%, pointing to strong longer term gains despite a bumpy few weeks around earnings, guidance, clinical data updates and the CEO change.
Spot similar stories where clinical momentum meets shifting expectations by scanning the 36 healthcare AI stocks that analysts have already filtered for you.Natera now combines strong clinical traction with a sharp pullback in the share price. The business looks powerful on the ground. The question is whether the current valuation still does it justice.
Most Popular Narrative: 23% Undervalued
Natera’s last close at $320.39 sits well below the analyst consensus Narrative fair value of $416.39, which the analyst consensus Narrative on Simply Wall St builds from detailed revenue and earnings forecasts using a 7.45% discount rate.
Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera). This will likely boost top-line revenue. Expanding clinical validation through large-scale trials (DARE, IMvigor011, PROCEED/FIND, etc.) and broadening indications is expected to lead to further payer adoption and reimbursement, especially for new tumor types and expanded Medicare coverage. This should drive higher ASPs and gross margins.
See why 20 investors see Natera as 23% undervalued.
Result: Fair Value of $416.39 (UNDERVALUED)
Still, Natera’s story could be knocked off course if richer P/E assumptions meet weaker profitability, or if reimbursement and policy shifts bite harder than expected.
Find out about the key risks to this Natera narrative.
Another View: Natera Through a Sales Multiple Lens
The analyst narrative and DCF style fair value put Natera in the “undervalued” camp, yet the market is already paying a rich price for each dollar of revenue. The P/S sits around 16x, compared with 10x for the wider US Biotechs group, 4.8x for peers, and a fair ratio of 10.8x that the market could move toward. That gap points to real valuation risk if sentiment cools or if investors start anchoring closer to industry norms.
For readers who prefer to lean on hard trading multiples rather than models, this split between the SWS DCF style view and today’s high P/S begs a simple question: Which signal do you trust more when expectations are already this full for Natera, the cash flow model or the revenue multiple?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling pulled between Natera’s promise and its price tag is natural, especially with sentiment this mixed. Act while the information is fresh, review both the concerns and the brighter spots, and weigh them against your own risk tolerance through the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Natera?
If Natera has sharpened your thinking on risk and reward, let that momentum carry over into fresh ideas using focused screeners built from hard data.
- Spot potential mispricings early and compare them with Natera by scanning a curated 33 high quality undervalued stocks that filters for quality fundamentals and compressed valuations.
- Strengthen the defensive side of your portfolio with a 30 resilient stocks with low risk scores that highlights businesses scoring well on balance sheet resilience and volatility.
- Get ahead of the crowd by reviewing a 19 high quality undiscovered gems that surfaces high quality companies many investors may not be watching yet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com